160 related articles for article (PubMed ID: 33315677)
1. Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
Ansquer C; Touchefeu Y; Faivre-Chauvet A; Leux C; Le Bras M; Régenet N; Fleury V; Maucherat B; Senellart H; Guyetant S; Carlier T; Scotet-Cérato E; Rauscher A; Frampas E; Kraeber-Bodéré F
Clin Nucl Med; 2021 Mar; 46(3):181-186. PubMed ID: 33315677
[TBL] [Abstract][Full Text] [Related]
2. 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation.
Christiansen CD; Petersen H; Nielsen AL; Detlefsen S; Brusgaard K; Rasmussen L; Melikyan M; Ekström K; Globa E; Rasmussen AH; Hovendal C; Christesen HT
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):250-261. PubMed ID: 29116340
[TBL] [Abstract][Full Text] [Related]
3. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors.
Sharma A; Das CJ; Makharia GK; Arora G; Kumar R
Clin Nucl Med; 2020 Nov; 45(11):848-853. PubMed ID: 32657875
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors.
Zhou Z; Wang Z; Zhang B; Wu Y; Li G; Wang Z
Front Endocrinol (Lausanne); 2021; 12():727327. PubMed ID: 34539577
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms.
Veenstra EB; de Groot DJA; Brouwers AH; Walenkamp AME; Noordzij W
Clin Nucl Med; 2021 Mar; 46(3):195-200. PubMed ID: 33323729
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
9. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
10. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
11. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients.
Berzaczy D; Giraudo C; Haug AR; Raderer M; Senn D; Karanikas G; Weber M; Mayerhoefer ME
Clin Nucl Med; 2017 Sep; 42(9):669-674. PubMed ID: 28682844
[TBL] [Abstract][Full Text] [Related]
12. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma.
Sharma P; Arora S; Karunanithi S; Khadgawat R; Durgapal P; Sharma R; Kandasamy D; Bal C; Kumar R
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):69-76. PubMed ID: 24740163
[TBL] [Abstract][Full Text] [Related]
14. The Accessory Spleen Is an Important Pitfall of 68Ga-DOTANOC PET/CT in the Workup for Pancreatic Neuroendocrine Neoplasm.
Rufini V; Inzani F; Stefanelli A; Castaldi P; Perotti G; Cinquino A; Indovina L; Rindi G
Pancreas; 2017 Feb; 46(2):157-163. PubMed ID: 27846139
[TBL] [Abstract][Full Text] [Related]
15. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor.
Sharma P; Naswa N; Kc SS; Alvarado LA; Dwivedi AK; Yadav Y; Kumar R; Ammini AC; Bal C
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2194-202. PubMed ID: 25030618
[TBL] [Abstract][Full Text] [Related]
17. Multifocal extra-adrenal paraganglioma evaluated with different PET tracers: comparison between 18F-FDG, 18F-DOPA and 68Ga DOTANOC PET/CT.
Treglia G; Cardillo G; Stefanelli A; Di Franco D; Enang GN; Giordano A; Rufini V
Clin Nucl Med; 2013 Dec; 38(12):e458-62. PubMed ID: 23486329
[TBL] [Abstract][Full Text] [Related]
18. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.
Thuillier P; Maajem M; Schick U; Blanc-Beguin F; Hennebicq S; Metges JP; Salaun PY; Kerlan V; Bourhis D; Abgral R
Clin Nucl Med; 2021 Feb; 46(2):111-118. PubMed ID: 33234927
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.
Ambrosini V; Campana D; Bodei L; Nanni C; Castellucci P; Allegri V; Montini GC; Tomassetti P; Paganelli G; Fanti S
J Nucl Med; 2010 May; 51(5):669-73. PubMed ID: 20395323
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma.
Sharma P; Thakar A; Suman K C S; Dhull VS; Singh H; Naswa N; Reddy RM; Karunanithi S; Kumar R; Kumar R; Malhotra A; Bal C
J Nucl Med; 2013 Jun; 54(6):841-7. PubMed ID: 23520216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]